Internal mammary nodes are addressed in high risk group of patients of carcinoma breast. Though there is crossover of lymphatics across the mid-line, only ipsilateral internal mammary nodes are evaluated or treated. Considering the negative impact on survival of patients with inner quadrant tumor, do we need to treat bilateral internal mammary nodes?